New Delhi
The Indian pharmaceutical sector is predicted to experience mixed results this quarter, with slow growth expected in branded formulations. According to analysts, the sector’s revenue is projected to grow by 12 per cent year-on-year (YoY) and 5 per cent quarter-on-quarter (QoQ).
Companies like Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin, and Mankind Pharma are expected to perform well on a YoY basis. However, the overall Indian Pharmaceutical Market (IPM) is projected to see only 8 per cent growth, mainly due to minimal drug price inflation tied to the Wholesale Price Index (WPI).
Sun Pharma’s domestic business is expected to grow moderately, while its U.S. business may benefit from an expanded market share of generic Revlimid. Growth in revenue, EBITDA, and PAT is forecasted at 7 per cent, 15 per cent, and 16 per cent QoQ.
Cipla’s domestic business is predicted to grow, supported by the generic Lanreotide, while its U.S. segment is expected to remain stable.
Dr. Reddy’s India business may see double-digit growth due to a vaccine distribution agreement, but U.S. growth is projected to remain flat. Zydus Lifesciences’ U.S. sales may decline sequentially, while its wellness business may see moderate growth.
Lupin and Mankind are also expected to show growth in their domestic businesses, with Mankind’s consumer business showing signs of recovery and exports improving.
